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Abstract 
Background: Mild therapeutic hypothermia (MTH) is believed to reduce the effectiveness of antiplatelet 
drugs. Effective dual-antiplatelet therapy after percutaneous coronary intervention (PCI) is mandatory 
to avoid acute stent thrombosis. The effectiveness of ticagrelor in MTH-treated out-of-hospital cardiac 
arrest (OHCA) survivors is still a matter of debate. The aim of the study was to evaluate the impact  
of MTH on the platelet-inhibitory effect of ticagrelor in comatose survivors of OHCA treated with pri-
mary PCI.
Methods: Eighteen comatose survivors of OHCA with acute coronary syndrome undergoing immediate 
PCI treated with MTH were compared with 14 patients with uncomplicated primary myocardial infarc-
tion after PCI, matched for gender and age, in a prospective, single-center, observational study. Platelet 
aggregation was evaluated using VerifyNow P2Y12 point-of-care testing at 3 time points: admission (T0), 
during MTH (T1), and 48–72 h after rewarming (T2).
Results: Ticagrelor effectively inhibits platelet aggregation in OHCA patients subjected to MTH and 
in all patients in the control group. The effectiveness of ticagrelor did not differ between the MTH group 
and the control group (p = 0.581). In 2 cases in the MTH population, the platelet response to ticagrelor 
was inadequate, and in one of them it remained insufficient during the re-warming phase. There was 
no stent thrombosis in these patients. 
Conclusions: The present study confirmed the effectiveness of ticagrelor to inhibit platelets in myo-
cardial infarction patients after OHCA treated with primary PCI undergoing hypothermia. The use of 
cooling was not associated with an increased risk of stent thrombosis. (Cardiol J)
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The leading cause of out-of-hospital cardiac 
arrest (OHCA) is myocardial infarction (MI) [1, 2]. 
Patients who survive cardiac arrest (CA) due to 
acute coronary syndrome should therefore undergo 
emergency coronary angiography, because 30–40% 
of them either have a totally occluded infarct-
related artery or an unstable coronary lesion [2–4]. 
Aggressive post-CA care, such as coronary artery 
reperfusion and mild therapeutic hypothermia 
(MTH), doubles the number of patients that sur-
vive to hospital discharge [5]. Effective dual-anti-
platelet therapy (DAPT) including acetylsalicylic 
acid (ASA) and a P2Y12 receptor inhibitor following 
a percutaneous coronary intervention (PCI) is 
mandatory to avoid acute stent thrombosis (ST). 
Whole-body ischemia caused by CA as a result of 
reperfusion injury following resuscitation often 
causes systemic inflammatory response syndrome, 
which disrupts the coagulation system and platelet 
function. Moreover, post-resuscitation myocardial 
dysfunction results in a decreased stroke volume, 
which, by reducing intestinal blood flow, may lead to 
an impaired absorption of antiplatelet drugs. MTH 
(32–34°C) has become the standard therapeutic 
option for improving neurological outcomes, and 
thus survival rates, after OHCA [3]. MTH inhib-
its the activation of the coagulation system while 
activating platelet aggregation [6, 7]. Cooling has 
been shown to augment adenosine diphosphate 
(ADP)-induced platelet aggregation, resulting in 
the reduced effectiveness of antiplatelet drugs [8]. 
Some previous studies have suggested that pa-
tients undergoing PCI and MTH after OHCA are 
at a higher risk of acute ST [9–12]. Other studies, 
however, including some meta-analyses, indicate 
that this risk is not actually increased in such 
patients [13–16]. Therefore, it is particularly im-
portant to assess the effectiveness of antiplatelet 
therapy in patients undergoing MTH after PCI. In 
this setting, ticagrelor should be the drug of choice 
before clopidogrel due to its better absorption, 
faster metabolism, quicker onset of action, and 
its lack of requirement for metabolic activation 
[17–21]. The VerifyNow-P2Y12 (VN-P2Y12) test we 
used measures the extent of platelet aggrega-
tion in the presence of ticagrelor; its reliability in 
platelet aggregation assessment in patients with 
MTH has been previously established [19]. We 
therefore aimed to test platelet function follow-
ing administration of ticagrelor in OHCA patients 
undergoing PCI, who were subjected to MTH for 
24 h, and compare the results to a matched patient 
group with MI without MTH. The aim of the study 
was to evaluate the impact of MTH on the platelet- 
-inhibiting effect of ticagrelor in comatose survi-
vors of OHCA who underwent primary PCI.
Methods
We conducted a prospective, single-center 
observational study. The protocol was approved 
by the Jagiellonian University Ethics Committee 
in Krakow. Written informed consent was obtained 
from patients regaining consciousness after CA and 
conscious patients with acute coronary syndrome. 
Therapeutic hypothermia was achieved by using 
an endovascular cooling device (Zoll Medical Cor-
poration Chelmsford, MA) to a target temperature 
of 32.0°C maintained for 24 h. Subsequently, re-
warming was performed at a rate of 0.2°C/h. 
The inclusion criteria for this study were pa-
tients aged 18 years or older, who had OHCA from 
an MI with return of spontaneous circulation, who 
survived 24 h after admission and were treated 
with DAPT. The exclusion criteria included known 
coagulopathy, anticoagulation with a vitamin K an-
tagonist (international normalized ratio within the 
therapeutic range), intake of a direct oral antico-
agulant, effective inhibition of platelet function on 
admission, MTH pre-hospital, periprocedural use 
of glycoprotein IIb/IIIa receptor inhibitor, or those 
who were already taking clopidogrel, prasugrel, 
or ticagrelor. Patients were enrolled in the MTH 
group between January 2014 and January 2016. 
The control group consisted of gender- and age- 
-matched patients with uncomplicated MI after un-
dergoing a primary PCI and were admitted between 
December 2015 and August 2017. During MTH, 
all patients received an IV injection of analgesic 
opioid and sedation drugs. Neuromuscular blockade 
was often used according to the protocol of MTH. 
A loading dose (LD) of 300 mg ASA and 180 mg 
ticagrelor were administered via a nasogastric tube 
on admission, followed by 75 mg ASA once daily 
and 90 mg ticagrelor twice daily. The control group 
patients were administered ASA and ticagrelor 
orally according to the same protocol. The mean 
time between the first maintenance dose of ticagre-
lor (270 mg) and blood sampling in the MTH group 
was 495 ± 219 min. Prior to the procedure, platelet 
function was assessed using VN-P2Y12 point-of-care 
testing (Accumetrics Ltd., San Diego, CA, USA). 
A cut-off value below 194 platelet reactivity units 
(PRU) was adopted as evidence of a P2Y12 effec-
tive platelet function inhibition [22, 23]. Platelet 
aggregation was evaluated at 3 timepoints: when 
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baseline blood samples were taken prior to LD (T0), 
when samples were drawn during MTH 12–24 h 
after LD (T1), and 48–72 h after re-warming (T2). 
All patients in the MTH group reached the target 
temperature (32°C) during sampling. The average 
core temperature between groups of patients after 
CA and control at the 3 timepoints were 35.3 ± 
± 0.6oC vs. 36.3 ± 0.5oC at T0, 32.2 ± 0.1oC vs. 
36.7 ± 0.4oC at T1, and 36.7 ± 0.1oC vs. 36.6 ± 0.4oC 
at T3, respectively. The key outcome variable 
was the level of effective platelet inhibition after 
ticagrelor administration, as assessed by VN-P2Y12, 
which was measured at the timepoints specified 
above. We also monitored the presence of ST [24] 
and the occurrence of major bleeding as defined 
by the Bleeding Academic Research Consor-
tium (BARC) for bleeding classification [25]. The 
VN-P2Y12 assay we used in our study was a point-of- 
-care test, which is widely used to assess residual 
platelet reactivity in patients with MTH [26–29].
Statistical analysis
All statistical analyses were carried out using 
SAS software (version 4.0, SAS Institute Inc.). 
Categorical variables were presented as numbers 
of subjects and percentages. Continuous variables 
were analyzed for normal distribution using the 
Shapiro-Wilk test and were presented as mean ± 
standard deviation for normal distribution and as 
median values with lower and upper quartiles for 
non-normal distribution. Differences for continu-
ous variables between groups (MTH vs. control) 
were analyzed using a parametric Student’s test or 
Mann-Whitney U-test, as appropriate. Categorical 
data were compared using the c2 test or c2 test with 
Yates’ correction. P values less than 0.05 were 
considered significant 
Sample size calculation 
Based on previously published data involving 
patients with ST-segment elevation MI [30] and our 
own database [7] and considering values of PRU 
Mi1 = 46 and PRU Mi2 = 105 for both groups, 
respectively, we estimated that at least 17 patients 
were required to reach statistical significance us-
ing a power of 80% and a 2-sided a-level of 0.05, 
d = 60. 
Results
Patient characteristics
We prospectively included 18 patients who 
were admitted for an acute MI after OHCA and 
subsequently underwent primary PCI and were 
subjected to MTH for 24 h. They were compared 
to 14 matched patients who were admitted to the 
hospital due to MI and were undergoing PCI but 
were not in CA (control group). There was no 
difference in demographics, medical history, or 
periprocedural details between the groups. No 
patient in the control group was treated with opi-
ates during transport or during hospitalization. 
The baseline clinical characteristics are shown in 
Table 1, the characteristics of the MTH group are 
shown in Table 2, and hospitalization details are 
depicted in Table 3. 
Platelet count in patients in the MTH group 
decreased significantly after implementing MTH 
from 194 ± 52 [10–3/µL] (T0) to 149 ± 38 [10–3/
µL] (T1) (p < 0.001). This phenomenon persisted 
Table 1. Clinical characteristics.
Variable MTH group (n = 18) Control group (n = 14) P
Males 14 (78%) 12 (86%) 0.909
Age 68 ± 10 66 ± 9 0.742
History of MI 1 (6%) 2 (14%) 0.819
History of revascularization 2 (11%) 2 (14%) 0.788
Arterial hypertension 13 (72%) 10 (71%) 0.729
Diabetes mellitus type 2 5 (28%) 3 (21%) 1
Obesity 8 (44%) 2 (14%) 0.149
Stroke 1 (6%) 0 (0%) 0.898
Dyslipidemia 9 (50%) 6 (43%) 0.964
Tobacco smoking 5 (28%) 2 (14%) 0.628
Peripheral artery disease 1 (6%) 2 (14%) 0.819
Values are shown as mean ± standard deviation (SD) or number (percentage); MI — myocardial infarction; MTH — mild therapeutic hypothermia
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after the re-warming phase with a platelet count of 
141 ± 45 [10–3/µL] (T2), (Table 4). 
Antiplatelet results using VN-P2Y12
Platelet reactivity unit values did not differ 
significantly between the MTH group and the 
control group in any of the evaluated timepoints. In 
the MTH population, the average PRU after a LD 
of ticagrelor fell from 265 ± 41 at the baseline (T0), 
to 87 ± 89 at T1 (p = 0.44). There was an increase 
in the percentage of mean platelet inhibition from 
0.2 ± 0.9 (T0) to 67 ± 3 (T1) (p = 0.856) and at T1, 
2 out of 18 (11%) patients had inadequate platelet 
inhibition (p = 0.851). After re-warming, we re-
corded sustained antiplatelet effect of ticagrelor 
with a PRU value of 64 ± 53 (T2) and mean platelet 
inhibition percentage of 75 ± 19 (T2). All patients 
except 1 (5.5%) in T2 demonstrated effective 
inhibition of platelets with ticagrelor (Figs. 1–3). 
Similar results were observed in the control group 
(Table 5). 
Stent thrombosis and bleeding
No cases of ST occurred during hospitaliza-
tion in either group. In the MTH group, 6 (34%) 
patients experienced BARC 3a bleeding vs. none 
in the control group (p = 0.052; Table 3). In 
2 subjects, the bleeding affected the upper gastro-
Table 2. Characteristics of mild therapeutic  
hypothermia (MTH) group (n = 18).
Cardiac arrest data
Initial cardiac arrest rhythm:
VF/VT 15 (83%)
Asystole 1 (6%)
Pulseless electrical activity 2 (11%)
Time to ROSC [min] 21 ± 15
Witness 18 (100%)
Bystander CPR 11 (61%)
Condition at admission to hospital
GCS score (3–4) 10 (56%)
GCS score (5–6) 8 (44%)
Cardiogenic shock 3 (17%)
Circumstances and details of MTH
Time to MTH [min] 129 ± 51
Total time of MTH [min] 1480 ± 149
Neurological outcome
Good neurological outcome  
at discharge
12 (67%)
Death during hospitalization 1 (6%)
Values are shown as mean ± standard deviation or number (per-
centage); CPR — cardiopulmonary resuscitation; GCS — Glasgow 
Coma Scale; ROSC — return of spontaneous circulation;  
VT/VF — ventricular tachycardia/ventricular fibrillation
Table 3. Hospitalization details.
Variable MTH group  
(n = 18)
Control group  
(n = 14)
P
Cardiogenic shock at admission 3 (17%) 0 (0%) 0.321
STEMI 9 (50%) 8 (57%) 0.964
Acute coronary occlusion 10 (56%) 9 (50%) 0.892
MVD (2 or 3) 9 (50%) 7 (50%) 0.722
PCI success 17 (94%) 14 (100%) 0.898
Cardiogenic shock during hospitalization 8 (44%) 0 (0%) 0.014
Stent thrombosis 0 (0%) 0 (0%) –
Pneumonia 12 (67%) 0 (0%) 0.001
Bleeding BARC 3a 3 (17%) 0 (0%) 0.321
Bleeding BARC 3b 3 (17%) 0 (0%) 0.321
Major bleeding 6 (33%) 0 (0%) 0.052
Renal failure 13 (72%) 1 (7%) 0.001
GFR 54 ± 22 78 ± 16 0.009
Stroke 2 (11%) 0 (0%) 0.492
Values are shown as mean ± standard deviation or number (percentage); BARC — Bleeding Academic Research Consortium; GFR — glomerular 
filtration rate; MTH — mild therapeutic hypothermia; MVD — multi-vessel disease; PCI — percutaneous coronary intervention; STEMI — ST-
-segment elevation myocardial infarction
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Table 4. Platelet count.
Platelet count [10–3/µL] MTH group (n = 18) Control group (n = 14) P
Basal (T0) 194 ± 52 232 ± 52 0.166
MTH (T1) 149 ± 38 223 ± 50 0.004
NT (T2) 141 ± 45 208 ± 38 0.004
Values are shown as mean ± standard deviation; MTH — mild therapeutic hypothermia; NT — normothermia; T0 — after admission; T1 — 12–24 h  
after percutaneous coronary intervention; T2 — 48–72 h after percutaneous coronary intervention
Table 5. Sample collection and results of VerifyNow-P2Y12 test in mild therapeutic hypothermia (MTH) 
group versus control group.














PRU 265 ± 41 251 ± 42 0.44 87 ± 89 31 ± 38 0.110 64 ± 53 41 ± 28 0.081
Percentage of platelet 
inhibition
0.2 ± 0.9 0.4 ± 1.3 0.856 67 ± 31 86 ± 16 0.202 75 ± 19 83 ± 12 0.169
Number of patients with 
satisfactory effect  
(PRU < 194)
– – – 16 (89%) 14 (100%) 0.581 17 (94%) 14 (100%) 0.898
Values are shown as mean ± standard deviation; number of patients with given score (%); PRU — platelet reactivity units; T0 — after admission; 
T1 — 12–24 h after percutaneous coronary intervention; T2 — 48–72 h after percutaneous coronary intervention; PRU T0 statistical power: 0.21 
(Mi1 = 264.9; Mi2 = 246.1; d = 44.9; a = 0.05); PRU T1: statistical power: 0.51 (Mi1 = 86.7; Mi2 = 31.1; σ = 75.63; a = 0.05); PRU T3 statistical 






















































Figure 1. Data are presented as peak platelet reactiv-
ity units (PRUs) in the primary percutaneous coronary 
intervention-mild therapeutic hypothermia (PCI-MTH) 
group (black bars) and the control group (blue bars) at 
baseline, during hypothermia at T1 (12–24 h), and after 
the rewarming phase at T2 (48–72 h) after the ticagre-
lor loading dose. Thresholds at 194 PRU indicate high 
on-treatment reactivity. Mean ± standard deviation is 
shown. The statistical power calculations used at each 
time point are as follows: baseline: statistical power: 
0.21 (Mi1 = 264.9; Mi2 = 246.1; d = 44.9; a = 0.05), 
T1 — statistical power: 0.51 (Mi1 = 86.7; Mi2 = 31.1; 
d = 75.63; a = 0.05), T2 — statistical power: 0.27 (Mi1 = 
= 63.6; Mi2 = 41.3; d = 44.7; a = 0.05); p < 0.05; 
ADP — adenosine diphosphate.
Figure 2. VerifyNow platelet reactivity in P2Y12 assay 
(Accumetrics, Inc., San Diego, CA, USA). Data show 
a comparison of the antiplatelet effect between the pri-
mary percutaneous coronary intervention-mild therapeu-
tic hypothermia (PCI-MTH) group (black bars) and the 
control group (blue bars) at baseline, T1 (12–24 h), and 
T2 (48–72 h) after a loading dose of ticagrelor. Platelet re-
activity is expressed as the percentage of platelet inhibi-
tion. Mean ± standard deviation is shown, p < 0.05. The 
statistical power calculations used at each time point are 
as follows: baseline: statistical power: 0.05 (Mi1 = 0.22; 
Mi2 = 0.35; d = 1.13; a = 0.05), T1 — statistical power: 
0.48 (Mi1 = 67.4; Mi2 = 86.4; d = 26.9; a = 0.05), T2 — 
statistical power: 0.25 (Mi1 = 74.7; Mi2 = 82.6; d = 16.6; 
a = 0.05); p < 0.05; ADP — adenosine diphosphate.
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intestinal tract, and in 2 other cases, bleeding was 
related to arterial puncture site bleeding. In the last 
2 cases, bleeding from the mucosa of the nostrils 
after insertion of a nasogastric tube and bronchial 
bleeding were observed. 
Discussion
The main finding of the present study was that 
ticagrelor effectively inhibited platelet aggrega-
tion in a population of OHCA patients subjected 
to MTH for 24 h while undergoing primary PCI. 
The effectiveness of ticagrelor did not differ be-
tween either group, which is in line with previous 
reports [14, 19]. In 2 cases in the MTH population, 
platelet response to ticagrelor was inadequate, 
and in 1 of them it remained insufficient during 
the re-warming phase. In the first case, ticagrelor 
resistance may have been associated with impaired 
drug absorption secondary to reduced gastric 
and intestinal perfusion from decreased cardiac 
output in the course of cardiogenic shock [26]. 
In the second case, the resistance of platelets to 
ticagrelor during hypothermia which persisted in 
the re-warming phase may have been due to pre-
activation of platelets caused by a higher baseline 
expression of activated glycoprotein IIb/IIIa in the 
course of advanced diabetes in a subject dialyzed 
for many years. This is in line with a previous 
publication that explicitly addressed the impact 
of renal impairment on residual platelet reactivity 
during DAPT in VN-P2Y12 assessment [27, 28]. Of 
importance, according to previous pharmacody-
namic and pharmacokinetic studies, ticagrelor can 
be safely used in patients with renal insufficiency, 
including those on dialysis [29]. 
To assess the potential impact of MTH on 
the antiplatelet effect of ticagrelor, we compared 
patients undergoing hypothermia after CA with the 
control group of patients with only MI. The degree 
of platelet inhibition 12–24 h after administration 
of ticagrelor in the MTH group was similar to that 
observed by the TICOMA investigators [18] and 
others, where sufficient platelet inhibition was 
achieved just after 3 h [18] and persisted during the 
24–48 h period after the LD [18, 19]. Similar results 
were reported by Tileman et al. [15], who showed 
that the degree of platelet inhibition measured by 
impedance aggregometry 24 h after an LD of tica-
grelor did not differ between 27 hypothermic and 
10 normothermic patients with acute MI. Based 
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Figure 3. A. Platelet reactivity by treatment. VerifyNow 
P2Y12 assay results: Individual results for the VerifyNow 
P2Y12 assay (Accumetrics, Inc., San Diego, CA, USA) 
are expressed as P2Y12 reaction units (platelet reactivity 
units [PRU]) at baseline (0 h) and each measured time 
point: T1 (12–24 h) and T2 (48–72 h) after ticagrelor load-
ing dose. Platelet inhibition with 90 mg ticagrelor twice 
daily in n = 18 primary percutaneous coronary interven-
tion-mild therapeutic hypothermia (PCI-MTH) patients 
(empty blue squares) is shown in comparison to n = 14 
normothermic patients after primary PCI in the control 
group (red dots). Solid lines with error bars indicate 
the least-square means (95% confidence interval). The 
dashed line indicates a level of 194 PRU as a threshold 
for high platelet reactivity. There is no significant differ-
ence between the groups (all p > 0.01); ADP — adeno-
sine diphosphate; B. Inhibition of platelet aggregation 
by VerifyNow P2Y12 assay (Accumetrics, Inc., San Diego, 
CA, USA) at baseline (0 h), T1 (12–24 h), and T2 (48–72 h) 
after ticagrelor loading and maintenance therapy in 
n = 18 primary percutaneous coronary intervention-
-mild therapeutic hypothermia (PCI-MTH) patients (blue 
squares) and n = 14 control group (red dots). Solid 
lines with error bars indicate the least-square means 
(95% confidence interval). The dashed line indicates 
a level of 194 platelet reactivity units (PRU) as a thresh-
old for high platelet reactivity; p > 0.01; ADP — adenos-
ine diphosphate.
6 www.cardiologyjournal.org
Cardiology Journal 20XX, Vol. XX, No. X
and MTH and were given ticagrelor, the platelet 
reactivity index (PRI) value after 24 h was within 
the effective range in all cases in the assessment of 
PRI/vasodilator-stimulated phosphoprotein (VASP) 
[31]. Different observations were made by Ibrahim 
et al. [9], who found PRI/VASP values above 50% 
in 3 (33.33%) out of 10 PCI-MTH patients on 
ticagrelor treatment. Similarly, Kander et al. [33] 
recognized that in 7 (50%) out of 14 patients with 
dual-platelet inhibition, the effect of ticagrelor on 
platelets was still insufficient 12–24 h after induc-
tion of MTH and did not reach the target VASP 
PRI < 50 when measured by flow cytometry-based 
VASP. The authors of that study hypothesized that 
a probable cause of this phenomenon could be de-
layed gastric emptying in the MTH group [9, 32]. 
Our results confirm that a high rate of effec-
tive blocking of the P2Y12 receptor by ticagrelor in 
the MTH group translated into a lack of ST, which 
is contrary to doubts raised by earlier researchers 
emphasizing the attenuated effect of P2Y12 inhibi-
tors caused by cooling [10, 11, 33]. In all patients 
included in our study, initiation of hypothermia was 
preceded by the administration of an LD of ASA 
and ticagrelor. The ATLANTIC trial highlights the 
importance of administering ticagrelor as early as 
possible to affect clinical endpoints [34]. In our 
study, we assessed platelet reactivity as a surro-
gate marker of thrombotic complication, because 
VN-P2Y12 assessment has previously been used 
as a measure of platelet reactivity in response to 
MTH [19]. Overall, we did not observe ST or re-
current MI or unscheduled re-angiography in the 
MTH group. Similar results with 0% ST in OHCA 
patients undergoing MTH and PCI were observed 
by other researchers in groups of 27 [15], 33 [35], 
and 45 [36] patients, which was only slightly 
different from the 2.5% ST reported ST among 
40 patients [37]. In all of the studies except one 
[36], subjects received pre-treatment with a full 
dose of heparin, ASA, and an LD of P2Y12 inhibitor 
before cooling, which possibly minimized the risk 
for ST as described earlier [34]. Different results 
were presented in several other reports involving 
small groups of patients, indicating a relationship 
between the use of MTH and the occurrence of ST, 
the frequency of which varied from 10.9% to 49% 
[11, 33]. In a study by Ibrahim et al. [9], 4 (14.8%) 
patients from a group of 27 patients undergoing 
MTH and PCI after OHCA had ST. However, no 
subject from this group was given a LD of P2Y12 
antagonist as pretreatment [9]. Another study of 
a small cohort of patients treated with OHCA in 
conjunction with MTH where hypothermia was 
maintained for 24–48 h also observed a high oc-
currence of ST in 5 (45.5%) of 11 subjects. The 
average time from PCI to ST was 174 h, indicating 
that thrombotic incidents may have been associated 
with causes other than MTH [33]. 
A second important issue regarding prevention 
of acute and subacute ST risk in the MTH group 
is related to avoiding implantation of undersized 
stents, which may occur as a result of underes-
timating the diameter of an infarct-related artery 
secondary to coronary vasospasm in the course 
of cooling [38]. In 2014 and 2015, Joffre et al. [11] 
as well as Gouffran et al. [10] observed a 10.9% 
incidence of ST in the population they researched. 
Both studies were conducted retrospectively 
without comparative groups. In the first study, 
46 (83.6%) out of 55 patients were in cardiogenic 
shock and required continuous vasopressor in-
fusion [11]. This may have promoted coronary 
vasoconstriction and potentially impacted the 
operator’s assessment of stent sizing, which may 
have led to length overestimation (average stent 
length of 26 mm) and stent diameter under-sizing 
with suboptimal expansion that could facilitate risk 
of ST. Hypothermia in this group was maintained 
for 24 h with a re-warming phase up to the next 
24 h. The average delay for ST after baseline in 
this study was 3 ± 1.7 days, and in 2 (3.6%) out of 
55 cases ST occurred within 24 h, while in the other 
4 (7.2%) cases it occurred on the third day or later. 
Importantly, only 53% of OHCA patients in this 
study were pre-treated with ASA and 51% were 
pre-treated with heparin before stent implantation, 
and none of them had received DAPT [11]. In the 
second study [10], MTH with the re-warming phase 
was maintained for 24–36 h. The median time from 
PCI to ST was 2 days (mean time: 2.5 ± 2.3 days). 
Angiographically-confirmed ST during the first 48 h 
occurred in only 5 (4.9%) cases, while the remain-
ing 3 (2.9%) were recognized only based on clinical 
suspicion [10] and, according to the BARC definition 
of ST [23], could be qualified only as a “possible 
event”. A meta-analysis of 5 clinical trials involving 
a total of 290 patients who underwent PCI treat-
ment with MTH showed an incidence of ST of 6%, 
which was higher than reported in non-hypothermia 
conditions. Importantly, the study mentioned above 
did not confirm significant differences between the 
frequency of ST between the groups treated with 
clopidogrel and those receiving newer agents (tica-
grelor or prasugrel) [39]. 
The most compelling evidence regarding the 
relationship between the use of MTH and the 
risk of ST comes from a multicenter analysis by 
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Shah et al. [16], which included 49,109 patients 
who underwent a primary PCI, of whom 1,193 
underwent MTH. There was no difference in ST 
incidence between the MTH and non-MTH groups 
(3.9% vs. 4.7%), which was further confirmed by 
propensity-matched analysis [16]. Furthermore, 
a meta-analysis of 9 trials including 744 patients 
with acute MI, who underwent PCI and were ran-
domly assigned to either hypothermia or control 
treatment with target vessel revascularization, 
found no significant difference in the occurrence 
of ST between groups: ST incidence was 2.4% vs. 
0.2%, respectively, with a relative risk of 3.55 [0.80; 
15.87] (p = 0.09) [39]. 
The occurrence of serious bleeding (BARC 3a, 
3b) in our study was limited to the group of MTH 
patients with a frequency of 6 (33%) patients, which 
is similar to reports from some previous studies 
[12, 40] and slightly more than others [15, 16]. 
Given the small cohort we examined, it is possible 
that our observations could be accidental. In pre-
vious reports, bleeding complications were more 
often observed in hypothermia-treated patients 
only in smaller studies [40, 41] similar to ours, 
as opposed to observations of larger populations 
[16, 42, 43]. One potential mechanism behind the 
increased risk of bleeding in MTH-treated patients 
could be a decreased platelet count in blood serum 
persisting after re-warming. This is consistent with 
prior studies involving cooling patients [44] as well 
as coagulation disorders and most likely results 
from impaired production of clotting enzymes at 
temperatures below 32°C, which was previously 
studied by our group and others [7, 8].
Limitations of the study
There are several limitations in our study. 
VN-P2Y12 is a well-established and reliable method 
for evaluating response to P2Y12 inhibitors. How-
ever, verification of our results by another test 
could be an added value, especially because there 
is no validation of the different testing systems in 
hypothermic patients. Unfortunately, in our study, 
we did not carry out serial tests of platelet function, 
which prevents us from determining the minimum 
time required to achieve effective platelet inhibi-
tion after administration of an LD of ticagrelor. We 
also lack sufficient data to evaluate both the early 
pharmacokinetic and pharmacodynamic effects of 
ticagrelor administered through a nasogastric tube. 
The lack of a control group consisting of patients 
after CA resulted from difficulties in recruiting 
such patients due to ethical reasons. Our study 
was conducted in 1 center, and its limited sample 
size had sufficient power to assess the effective-
ness of platelet aggregation inhibition by ticagrelor 
but does not provide adequate statistical power to 
assess clinical endpoints.
Conclusions
The present study confirms the findings of the 
effectiveness of blocking platelets by ticagrelor 
in MI patients after OHCA treated with primary 
PCI undergoing hypothermia. The use of cooling 
was not associated with an increased risk of ST in 
patients in this very high-risk group, although it 
may be associated with a slightly increased risk 
of bleeding.
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